You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李強調研生物醫藥產業發展:加大政策支持 推動產業提質升級
國務院總理李強昨日(20日)在北京調研生物醫藥產業發展情況時強調,要加大高質量科技供給和政策支持,着力推動生物醫藥產業提質升級,研發生產更多優質高效的好藥新藥,不斷增進人民健康福祉。 李強在百濟神州(北京)生物科技瞭解有關新藥研發情況時稱,要及時發現臨牀價值高、轉化潛力大的創新藥項目,加強跟蹤服務,推動醫療機構配備使用。要大力培育優質企業,在人才及融資等方面給予政策支持,鼓勵企業深化國際合作,持續提升企業創新力及競爭力。 李強在調研中主持召開座談會。在聽取有關企業和投資、研發及醫療機構負責人發言後,李強指出,要注重運用人工智能全面賦能產業發展,提高藥物研發、臨牀試驗、診斷治療及生產流通等環節智能化水平。要強化產品研發、審評審批及管理使用等政策銜接和協同配合,優化藥品集採和談判議價機制,加大高水平創新藥應用指導力度。 李強還強調,要依靠創新促進中醫藥振興發展,充分運用現代科學的理論、技術及材料等,深化中醫藥基礎理論、診療規律及作用機理的研究闡釋,豐富治療方法,推進中醫藥現代化及產業化。(ta/w) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account